Administration of anti-CTLA-4 antibodies was demonstrated to result in a CD8+ T-cell-dependent tumour rejection and treatment doubled the numbers of mLama4- and mAlg8-specific T cells infiltrating the tumours of MCA sarcoma-bearing mice5. This evidence concerns the gene CTLA4 and sarcoma.